# US 2026/0062731 A1 · A loopable translator for the synthesis of repetitive proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062731 A1
- Document ID: US20260062731A1
- Status: Published application
- Kind: A1
- Application number: 19/108,209
- Filed: 2023-09-08
- Published: 2026-03-05
- Earliest claimed: 2022-09-08
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Stephen D. Fried; Sea On Lee
- Web page: https://patentgrep.com/patent/US20260062731A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12N 15/1031: {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- C12N 15/67: General methods for enhancing the expression
- C12N 15/85: for animal cells
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 2800/107: for mammalian
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12R 2001/125: Bacillus subtilis {; Hay bacillus; Grass bacillus}
- C12R 2001/19: Escherichia coli
- C12R 2001/645: Fungi {; Processes using fungi}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure is directed to a genetic construct for performing loopable translation, a kit comprising the genetic construct, and a method of producing biomaterials comprising a highly repetitive protein by use of the genetic construct.

## Claims

### Claim 1

A genetic construct for performing loopable translation, the construct comprising in the following order: (i) a 3′ portion of a Group I self-splicing intron; (ii) a C-terminal portion of a gene of interest, wherein the C-terminal portion of the gene of interest comprises a 3′-exonic context sequence at its 5′ end; (iii) a ribosome binding site (RBS); (iv) a N-terminal portion of the gene of interest, wherein the N-terminal portion of the gene of interest comprises a 5′-exonic sequence at its 3′ end; and (v) a 5′ portion of the Group I self-splicing intron.

### Claim 2 (depends on 1)

The genetic construct of claim 1, wherein the genetic construct further comprises an initiator codon (AUG) and a downstream box (DB) sequence after the ribosome binding site (RBS).

### Claim 3 (depends on 1, 2)

The genetic construct of claim 1 or claim 2, wherein the genetic construct further comprises a TEV protease cleavage site at the end of the C-terminal portion of a gene of interest.

### Claim 4 (depends on 1, 2, 3)

The genetic construct of any of claims 1-3, wherein the Group I self-splicing intron is a T4 bacteriophage thymidylate synthase (td) intron substituted with a Tetrahymena thermophila rRNA intron, Chlamydomonas reinhardii rRNA intron, or T4 bacteriophage sun Y intron substituted with a Tetrahymena thermophila rRNA intron.

### Claim 5 (depends on 1, 2, 3, 4)

The genetic construct of any of claims 1-4, wherein the 3′-exonic context sequence functions as an internal guide sequence (IGS) for site-specific splicing.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The genetic construct of any of claims 1-5, wherein the 5′-exonic context sequence functions as an internal guide sequence (IGS) for site-specific splicing.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The genetic construct of any of claims 1-6, wherein the gene of interest have a length of from 700 nucleotides to 1500 nucleotides.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The genetic construct of any of claims 1-7, wherein the gene of interest is a gene that encodes green fluorescent protein (GFP).

### Claim 9 (depends on 8)

The genetic construct of claim 8, wherein the GFP gene has the sequence of SEQ ID NO: 1.

### Claim 10 (depends on 9)

The genetic construct of claim 9, wherein the N-terminal portion of the GFP gene comprises nucleotides 1 to 52 of SEQ ID NO: 1 and the C-terminal portion of the GFP gene comprises nucleotides 53 to 241 of SEQ ID NO:1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The genetic construct of claim 1-10, wherein the 5′-exon context sequence includes at least 1 codon, at least 2 codons, at least 3 codons, at least 4 codons, or at least 5 codons.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The genetic construct of any of claims 1-11, wherein the 5′ exon context sequence wherein at least one codon is GGU (glycine).

### Claim 13 (depends on 8, 9, 10)

The genetic construct of claim 8-10, wherein the 5′-exon context sequence does not include a codon, but in which the N-terminal portion of the gene of interest ends with GGU (glycine).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The genetic construct of any of claims 1-13, wherein the 3′-exon context sequence includes at least 1 codon, at least 2 codons, at least 3 codons, at least 4 codons, or at least 5 codons.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The genetic construct of any of claims 1-14, wherein the 3′ exon context sequence wherein at least one codon is CUA (leucine).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The genetic construct of any of claims 1-15, wherein the gene of interest encodes a biofilm forming CsgA protein, dragline spidroin protein with soluble end-domains, a Squid Ring Teeth (SRT) protein, a collagen, or an mRNA-vaccine.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The genetic construct of any of claims 1-16, wherein the Group I self-splicing intron requires the use of at least two co-factors.

### Claim 18 (depends on 17)

The genetic construct of claim 17, wherein the co-factors are a divalent cation and a guanosine nucleoside.

### Claim 19 (depends on 18)

The genetic construct of claim 18, wherein the divalent cation is a magnesium cation.

### Claim 20 (depends on 17, 18, 19)

The genetic construct of any of claims 17-19, wherein the divalent cation is used in an amount from about 1 to about 30 mM to increase construct performance.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The genetic construct of any of claims 1-20, wherein the construct is pBAD-tdTEVDB.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The genetic construct of any of claims 1-21, wherein the genetic construct contains a mutation in a 36-base pair region covering the RBS, a RBS spacer, an initiator codon, or a DB for increasing translational efficiency and product yield.

### Claim 23 (depends on 22)

The genetic construct of claim 22, wherein the mutation is introduced using a modified error-prone PCR method.

### Claim 24 (depends on 22)

The genetic construct of claim 22, wherein the initiator codon is an initiator methionine.

### Claim 25 (depends on 23)

The genetic construct of claim 23, wherein the mutation is C-15A, G4C or C-15A/G4C.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A kit comprising:
a. the genetic construct of any of claims 1-25; and
b. at least two co-factors.

### Claim 27 (depends on 26)

The kit of claim 26, wherein the co-factors are a divalent cation and a guanosine nucleoside.

### Claim 28 (depends on 27)

The kit of claim 27, wherein the divalent cation is a magnesium cation.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of producing biomaterials, the method comprising the step of transforming a host cell with the genetic construct of any of claims 1-25, adding at least two co-factors, and culturing the host cell at a temperature of about 25° C. to about 37° C. to produce a biomaterial.

### Claim 30 (depends on 29)

The method of claim 29, wherein the host cell is a bacterial cell, a yeast cell, or a mammalian cell.

### Claim 31 (depends on 29, 30)

The method of claim 29 or claim 30, wherein the genetic construct further comprises an inducible promoter.

### Claim 32 (depends on 31)

The method of claim 31, wherein the inducible promoter is an Arabinose-inducible pBAD promoter or a GroES promoter.

### Claim 33 (depends on 29, 30, 31, 32)

The method of any of claims 29-32, wherein the host cell is a bacterial cell.

### Claim 34 (depends on 33)

The method of claim 33, wherein the bacterial cell is an E. coli or a gram-positive bacterium.

### Claim 35 (depends on 34)

The method of claim 34, wherein the gram-positive bacterium is Bacillus subtilis.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The method of any of claims 29-35, wherein the co-factors are a divalent cation and a guanosine nucleoside.

### Claim 37 (depends on 36)

The method of claim 36, wherein the divalent cation is a magnesium cation.

### Claim 38 (depends on 37)

The method of claim 37, wherein the magnesium cation is added to the culture in an amount of to about 1 to about 30 mM.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any of claims 29-38, wherein the biomaterial is dragline silk comprising spidroins, a biofilm comprising curli proteins such as curli subunit A (CsgA), looped extracellular matrix (ECM) proteins such as fibronectin, laminin, collagen, reticulin, keratin, and elastin, squid ring teeth (SRT) proteins, globular cage-like protein nanomaterials, or any combinations thereof.
